Bioventus Share Price Today
(NASDAQ: BVS)

Name: Bioventus Share Price Today (NASDAQ: BVS) - Bioventus Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bioventus share price is $10.19 & ₹886.21 as on 6 Mar 2025, 2.30 'hrs' IST

$10.19

▲

0.1

(0.99%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Bioventus share price in Dollar and Rupees. Guide to invest in Bioventus stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bioventus, along with analyst recommendations, forecasts, and comprehensive financials.

Bioventus share price movements

Today's Low: $10.07
Today's High: $10.37
$10.19
1.23%
Downside
Day's Volatility :2.94%
Upside
1.74%
52 Weeks Low: $3.90
52 Weeks High: $14.38
$10.19
61.73%
Downside
52 Weeks Volatility :72.88%
Upside
29.14%

Bioventus (BVS) Returns

Period	Bioventus Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.32%	2.1%	0.0%
6 Months	4.45%	-4.1%	0.0%
1 Year	95.54%	2.2%	0.0%
3 Years	-24.08%	11.8%	-11.6%

Bioventus (BVS) Key Statistics

in dollars & INR

Previous Close	$10.09
Open	$10.09
Today's High	$10.37
Today's Low	$10.065
Market Capitalization	$663.5M
Today's Volume	$108.8K
52 Week High	$14.38
52 Week Low	$3.9
Revenue TTM	$555.1M
EBITDA	$50.4M
Earnings Per Share (EPS)	$-0.61
Profit Margin	-7.11%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-24.76%

How to invest in Bioventus Stock (BVS) from India?

It is very easy for Indian residents to invest directly in Bioventus from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bioventus stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bioventus or BVS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bioventus or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bioventus shares which would translate to 0.085 fractional shares of Bioventus as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bioventus, in just a few clicks!

Returns in Bioventus (BVS) for Indian investors in Rupees

The Bioventus stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Bioventus investment value today

Current value as on today

₹2,02,443

Returns

₹1,02,443

(+102.44%)

Returns from Bioventus Stock

₹97,481 (+97.48%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Bioventus (BVS)

-50%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Bioventus Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Bioventus

Essex Woodlands Health Ventures
19.92%
Juniper Investment Co, LLC
10.62%
Nantahala Capital Management, LLC
6.16%
BlackRock Inc
4.27%
Vanguard Group Inc
3.77%
Driehaus Capital Management LLC
1.71%

Analyst Recommendation on Bioventus

Buy

71%Buy

14%Hold

14%Sell

Based on 7 Wall street analysts offering stock ratings for Bioventus(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Bioventus Stock (BVS)

What analysts predicted

Upside of 47.2%

Target:

$15.00

Current:

$10.19

Insights on Bioventus Stock (Ticker Symbol: BVS)

Price Movement
In the last 1 year, BVS stock has moved up by 97.5%
Decreasing Revenue
Revenue is down for the last 2 quarters, 151.21M → 138.96M (in $), with an average decrease of 8.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -23.99M → -4.82M (in $), with an average increase of 397.4% per quarter
BVS vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 135.7% return, outperforming this stock by 161.0%

BVS Bioventus Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$319.2M	↑ 25.83%
Net Income	$-12.2M	↓ 64.21%
Net Profit Margin	-3.82%	↑ 9.63%

	FY19	Y/Y Change
Revenue	$340.1M	↑ 6.57%
Net Income	$6.9M	↓ 156.12%
Net Profit Margin	2.01%	↑ 5.83%

	FY20	Y/Y Change
Revenue	$321.2M	↓ 5.58%
Net Income	$16.4M	↑ 139.54%
Net Profit Margin	5.11%	↑ 3.1%

	FY21	Y/Y Change
Revenue	$430.9M	↑ 34.17%
Net Income	$9.6M	↓ 41.59%
Net Profit Margin	2.22%	↓ 2.89%

	FY22	Y/Y Change
Revenue	$512.1M	↑ 18.85%
Net Income	$-213.4M	↓ 2326.07%
Net Profit Margin	-41.67%	↓ 43.89%

	FY23	Y/Y Change
Revenue	$512.3M	↑ 0.04%
Net Income	$-156.2M	↓ 26.79%
Net Profit Margin	-30.49%	↑ 11.18%

	Q2 FY23	Q/Q Change
Revenue	$137.1M	↑ 15.13%
Net Income	$-3.7M	↓ 96.32%
Net Profit Margin	-2.69%	↑ 81.32%

	Q3 FY23	Q/Q Change
Revenue	$120.8M	↓ 11.87%
Net Income	$-7.3M	↑ 98.4%
Net Profit Margin	-6.05%	↓ 3.36%

	Q4 FY23	Q/Q Change
Revenue	$135.4M	↑ 12.11%
Net Income	$-6.1M	↓ 16.53%
Net Profit Margin	-4.5%	↑ 1.55%

	Q1 FY24	Q/Q Change
Revenue	$129.5M	↓ 4.41%
Net Income	$-4.6M	↓ 25.03%
Net Profit Margin	-3.53%	↑ 0.97%

	Q2 FY24	Q/Q Change
Revenue	$151.2M	↑ 16.81%
Net Income	$-24.0M	↑ 424.99%
Net Profit Margin	-15.87%	↓ 12.34%

	Q3 FY24	Q/Q Change
Revenue	$139.0M	↓ 8.1%
Net Income	$-4.8M	↓ 79.89%
Net Profit Margin	-3.47%	↑ 12.4%

	FY18	Y/Y Change
Profit	$235.0M	↑ 31.06%

	FY19	Y/Y Change
Profit	$249.2M	↑ 6.04%

	FY20	Y/Y Change
Profit	$233.5M	↓ 6.29%

	FY21	Y/Y Change
Profit	$302.7M	↑ 29.63%

	FY22	Y/Y Change
Profit	$331.1M	↑ 9.37%

	FY23	Y/Y Change
Profit	$328.2M	↓ 0.87%

	Q2 FY23	Q/Q Change
Profit	$89.1M	↑ 20.57%

	Q3 FY23	Q/Q Change
Profit	$78.9M	↓ 11.53%

	Q4 FY23	Q/Q Change
Profit	$84.2M	↑ 6.78%

	Q1 FY24	Q/Q Change
Profit	$86.6M	↑ 2.88%

	Q2 FY24	Q/Q Change
Profit	$101.6M	↑ 17.26%

	Q3 FY24	Q/Q Change
Profit	$93.6M	↓ 7.9%

	FY18	Y/Y Change
Operating Cash Flow	$45.2M	↑ 138.83%
Investing Cash Flow	$-6.1M	↓ 89.86%
Financing Cash Flow	$-13.3M	↓ 142.42%

	FY19	Y/Y Change
Operating Cash Flow	$40.7M	↓ 9.9%
Investing Cash Flow	$-7.9M	↑ 29.68%
Financing Cash Flow	$-11.0M	↓ 17.39%

	FY20	Y/Y Change
Operating Cash Flow	$71.8M	↑ 76.35%
Investing Cash Flow	$-20.5M	↑ 159.1%
Financing Cash Flow	$-29.6M	↑ 170.01%

	FY21	Y/Y Change
Operating Cash Flow	$23.0M	↓ 67.98%
Investing Cash Flow	$-283.8M	↑ 1284.2%
Financing Cash Flow	$273.4M	↓ 1024.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$10.8M	↑ 333.53%
Investing Cash Flow	$33.5M	↓ 322.35%
Financing Cash Flow	$-62.2M	↓ 327.35%

Bioventus Technicals Summary

Sell

Neutral

Buy

Bioventus is currently in a neutral trading position according to technical analysis indicators.

Bioventus (BVS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bioventus Inc	-3.9%	4.45%	95.54%	-24.08%	-47.48%
Medtronic Plc	2.26%	4.07%	8.74%	-12.76%	0.68%
Edwards Lifesciences Corp.	0.07%	8.12%	-19.19%	-34.12%	12.08%
Boston Scientific Corp.	0.07%	27.33%	53.68%	143.5%	203.93%
Stryker Corporation	-0.63%	8.92%	9.84%	53.87%	125.87%
Abbott Laboratories	7.11%	21.64%	15.28%	15.75%	78.63%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bioventus Inc	9.44	NA	2.14	0.4	-0.25	0.02	NA	2.28
Medtronic Plc	28.75	28.75	1.87	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	30.5	30.5	5.57	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	83.9	83.9	1.85	2.86	0.09	0.05	NA	14.76
Stryker Corporation	50.89	50.89	2.85	13.49	0.15	0.07	0.01	54.1
Abbott Laboratories	18.34	18.34	2.52	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bioventus Inc	Buy	$663.5M	-47.48%	9.44	-7.11%
Medtronic Plc	Buy	$120.9B	0.68%	28.75	12.83%
Edwards Lifesciences Corp.	Buy	$42.0B	12.08%	30.5	76.75%
Boston Scientific Corp.	Buy	$154.8B	203.93%	83.9	11.07%
Stryker Corporation	Buy	$150.7B	125.87%	50.89	13.25%
Abbott Laboratories	Buy	$238.6B	78.63%	18.34	31.95%

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Organization	Bioventus
Employees	1030
CEO	Mr. Robert E. Claypoole
Industry	Healthcare

Management People of Bioventus

Name	Title
Mr. Mark L. Singleton	Senior VP & CFO
Mr. Anthony D'Adamio J.D.	Senior VP, General Counsel & Corporate Secretary
Mr. Robert E. Claypoole	President, CEO & Director
Mr. Mike Crowe B.S., M.B.A.	Senior Vice President of Operations
Mr. David Crawford	Vice President of Investor Relations & Treasurer
Ms. Katrina J. Church J.D.	Senior VP & Chief Compliance Officer
Ms. Helen Leupold	Senior VP & Chief Human Resources Officer
Mr. Larry Chen	Managing Director of China & Asia Pacific
Mr. Dave Venner	Senior VP & GM of Surgical

Important FAQs about investing in BVS Stock from India :

What is Bioventus share price today?

Bioventus share price today stands at $10.19, Open: $10.09 ; Previous Close: $10.09 ; High: $10.37 ; Low: $10.07 ; 52 Week High: $14.38 ; 52 Week Low: $3.90.

The stock opens at $10.09, after a previous close of $10.09. The stock reached a daily high of $10.37 and a low of $10.07, with a 52-week high of $14.38 and a 52-week low of $3.90.

Can Indians buy Bioventus shares?

Yes, Indians can invest in the Bioventus (BVS) from India.

With INDmoney, you can buy Bioventus at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bioventus at zero transaction cost.

How can I buy Bioventus shares from India?

It is very easy to buy Bioventus from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bioventus (BVS) be purchased?

Yes, you can buy fractional shares of Bioventus with INDmoney app.

What are the documents required to start investing in Bioventus stocks?

To start investing in Bioventus, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.